Systematic benchmarking of mass spectrometry-based antibody sequencing reveals methodological biases

Maria Chernigovskaya,Khang Le Quy,Maria Stensland,Sachin Singh,Rowan Nelson,Melih Yilmaz,Konstantinos Kalogeropoulos,Pavel Sinitcyn,Anand Patel,Natalie Castellana,Stefano Bonissone,Stian Foss,Jan Terje Andersen,Geir Kjetil Sandve,Timothy Patrick Jenkins,William S. Noble,Tuula A. Nyman,Igor Snapkow,Victor Greiff

DOI: https://doi.org/10.1101/2024.11.11.622451

2024-11-12

Abstract:The circulating antibody repertoire is crucial for immune protection, holding significant immunological and biotechnological value. While bottom-up mass spectrometry (MS) is the most widely used proteomics technique for profiling the sequence diversity of circulating antibodies (Ab-seq), it has not been thoroughly benchmarked. We quantified the replicability and robustness of Ab-seq using six monoclonal antibodies with known protein sequences in 70 different combinations of concentration and oligoclonality, both with and without polyclonal serum IgG background. Each combination underwent four protease treatments and was analyzed across four experimental and three technical replicates, totaling 3,360 LC-MS/MS runs. We quantified the dependence of MS-based Ab-seq identification on antibody sequence, concentration, protease, background signal diversity, and bioinformatics setups. Integrating the data from experimental replicates, proteases, and bioinformatics tools enhanced antibody identification. De novo peptide sequencing showed similar performance to database-dependent methods for higher antibody concentrations, but de novo antibody reconstruction remains challenging. Our work provides a foundational resource for the field of MS-based antibody profiling.

Immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the reproducibility and robustness of mass - spectrometry - based antibody sequencing (Ab - seq) under different experimental conditions. Specifically, through systematic benchmarking, the authors aim to quantify the performance of Ab - seq methods in identifying antibody sequences, especially the influence in the following aspects:

1. **Experimental and technical reproducibility**: Evaluate the impact of multiple experimental replicates and instrument - technical replicates on the consistency of results.
2. **Protease selection**: Compare the effects of different protease treatments on antibody sequence coverage.
3. **Background signal diversity**: Investigate how the presence of polyclonal IgG background in serum affects the detection of monoclonal antibodies.
4. **Antibody concentration**: Examine how different concentrations of antibody input affect sequence detection and coverage.
5. **Antibody sequence similarity**: Analyze how the sequence similarity between antibodies affects the accuracy of identification.
6. **Protein identification and quantification tools**: Compare the performance of different open - source proteomics software tools (such as MaxQuant, MSFragger, and Casanovo) in peptide - spectrum matching (PSM) and de novo sequencing.
7. **Peptide de novo sequencing**: Evaluate the performance of de novo sequencing methods under high - concentration antibodies and compare it with database - dependent methods.

Through these systematic evaluations, the authors hope to provide basic data for future improvement of Ab - seq experimental design and computational processes, thereby achieving more accurate and comprehensive characterization of serum antibody diversity. This will not only help to understand the adaptive immune mechanisms of the human immune system, but may also promote the development of a new generation of therapeutic drugs, vaccines, and diagnostic tools.